Drug conjugate compounds for stimulating the antitumor ... "Despite significant progresses made in the treatment of cancers with the development of immune checkpoint inhibitors (ICI), several cancers exhibit resistance to these agents. Certain tumors are considered immunologically cold tumors usually respond poorly to cancer immunotherapies such as immune checkpoint blockade (ICB) therapy, and thus there is a need to develop novel approaches for the treatment of such cancers. The present application discloses methods and uses for enhancing the anti-tumor immune response in a subject suffering from a Sortilin-expressing cancer and/or treating a subject suffering from a Sortilin-expressing cancer, such as a cancer resistant to an immunotherapy, through the administration of conjugate compounds comprising a Sortilin-targeting agent conjugated to an anticancer agent. Combination therapies comprising the conjugate compounds and an immunotherapy such as ICB are also disclosed."
https://patents.google.com/patent/WO2017088058A1/en